Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma

May 19th 2021

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.

TIL-Based Therapies Possess Potential for Cure in Metastatic Melanoma, But Questions Remain

May 18th 2021

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Dr. Rapisuwon on Clinical Trial Barriers in the United States in Mucosal Melanoma

May 12th 2021

Suthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Dr. Rapisuwon on the Potential Utility of Toripalimab in Melanoma Subtypes

May 4th 2021

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor Types

April 30th 2021

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Dr. Davies on Managing Melanoma During the COVID-19 Pandemic

April 28th 2021

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Dr. Rapisuwon on Frontline Immunotherapy Vs Targeted Therapy in Melanoma Subtypes

April 27th 2021

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma

April 27th 2021

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

First Patients Dosed With PVSRIPO, CT-0508, and TH1902 Boosts Hope for Novel Therapies in Melanoma and Other Solid Tumors

April 22nd 2021

The first patient with PD-1/PD-L1–refractory melanoma has been dosed in the phase 2 LUMINOS-102 trial, which will evaluate the safety and efficacy of PVSRIPO alone or in combination with a PD-1/PD-L1 inhibitor in this patient population.

Dr. Rapisuwon on Biologic Differences Between Mucosal and Cutaneous Melanoma

April 20th 2021

Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.

Darovasertib Shows Encouraging Activity in Metastatic Uveal Melanoma

April 19th 2021

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

31-Gene Expression Profile Test Improves Risk Assessment in Cutaneous Melanoma

April 15th 2021

Combining the 31-gene expression profile test with current American Joint Committee on Cancer staging guidelines may improve risk assessment in patients with cutaneous melanoma, as well as determine which patients could be candidates for more intense follow-up.

Chronic irAEs After Adjuvant Anti–PD-1 Therapy More Common Than Previously Recognized in High-Risk Resected Melanoma

April 15th 2021

Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

April 11th 2021

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Lifileucel Yields Durable Responses in Pretreated Advanced Melanoma

April 11th 2021

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

Adjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma

April 10th 2021

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Frontline Tebentafusp Significantly Improves OS in Metastatic Uveal Melanoma

April 10th 2021

Tebentafusp (IMCgp100) resulted in a highly significant and clinically meaningful improvement in overall survival when given as a frontline treatment in patients with metastatic uveal melanoma.